Tiziana Life Sciences Ltd. Common Shares (TLSA) is a publicly traded Healthcare sector company. As of May 19, 2026, TLSA trades at $1.38 with a market cap of $171.80M and a P/E ratio of 0.00. TLSA moved +2.96% today. Year to date, TLSA is -13.75%; over the trailing twelve months it is -6.76%. Its 52-week range spans $0.63 to $2.60. Rallies surfaces TLSA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Tiziana Life Sciences lifts target to $9 after 64% fatigue improvement, 35% SUV drop: Tiziana Life Sciences raised its 12-month price target to $9 from $8 after updated intranasal foralumab data showed disease stabilization in 14 secondary progressive MS patients and 9 (64%) experienced fatigue improvements. Early Phase 2a MSA imaging showed up to 35% PET SUV and 24% SUVR reductions.
| Metric | Value |
|---|---|
| Price | $1.38 |
| Market Cap | $171.80M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.60 |
| 52-Week Low | $0.63 |
| Volume | 243.75K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
TLSA analyst coverage data. Average price target: $0.00.